# SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

> **NCT04764214** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 61 (actual)

## Conditions studied

- NSCLC Stage IV
- EGFR Activating Mutation

## Interventions

- **DRUG:** 3rd generation EGFR-TKI
- **RADIATION:** Consolidative SRT

## Key facts

- **NCT ID:** NCT04764214
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-07-20
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764214, "SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04764214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*